Buy now, pay later and medicines: why the sector should think hard

What changed on 15 July 2026?

Under final rules which the FCA published in February 2026, deferred payment credit, being the interest-free model divided into twelve or fewer instalments and commonly termed buy now, pay later, entered the regulator's perimeter on 15 July 2026. Third-party lenders now require FCA authorisation or a place within the temporary permissions regime, whose registration window ran from mid-May to the start of July, with six months from Regulation Day in which to apply for full authorisation. They must conduct proportionate affordability and creditworthiness assessment before lending, the Consumer Duty applies, and checkouts must disclose payment schedules, amounts and the consequences of missing them.

The market being regulated had grown from approximately sixty million pounds in 2017 to over thirteen billion by 2024, with roughly one in five UK adults using the product, and the FCA's deputy chief executive framed the objective in a single proposition, namely that nobody should be lent to who cannot repay. Agreements concluded before Regulation Day remain unregulated, whilst everything subsequent operates under the regime.

For most of retail this constitutes a consumer-protection development with a favourable trajectory. For pharmacy it initiates a harder question, since regulation confers respectability, newly authorised lenders will market their healthcare credentials into every vertical carrying high order values, and the checkout they will most wish to occupy is the one this site has spent recent weeks describing, namely the private treatment plan priced in monthly hundreds.

Why is pharmacy tempted?

Because the arithmetic flatters every party at the point of sale. The oral GLP-1 analysis mapped a category carrying ongoing prices from £154 to £269 monthly with introductory offers engineered to convert, travel clinics invoice families in the hundreds, and TRT and hair-loss plans run to four figures annually.

Against figures of that order, an instalment button measurably improves conversion and average order value, the providers' materials say so because it is true, and a pharmacy observing its checkout abandonment holds a genuine commercial difficulty which the product genuinely addresses. Adding the competitive dynamic, in that a chain offering instalments converts the stretched patient whom a pharmacy without them loses, the temptation does not constitute foolishness but ordinary commercial reasoning applied to a product category within which, this article argues, ordinary commercial reasoning is the wrong instrument.

What is the debt-treatment entanglement?

What does regulation resolve, and what can it not?

The new regime resolves genuine harms and warrants acknowledgement accordingly. Affordability assessment addresses the preceding era of unassessed lending, the Consumer Duty compels outcome monitoring, checkout disclosure ends any pretence that instalments do not constitute debt, ombudsman access provides a route for those treated unfairly, and an authorisation gate carrying criminal consequences excludes the least scrupulous operators. This article would prefer that pharmacy patients encountering the product encounter the regulated version, and states so without irony.

What regulation cannot resolve is category fit. The FCA regulates how credit is sold rather than where it belongs, and a fully compliant, affordability-assessed, Consumer-Duty-monitored loan attached to a course of medicine continues to entangle treatment with debt, continues to concentrate upon the financially stretched, and continues to place a default clause within a clinical relationship. The strongest version of the contrary case, being that regulation has rendered the product sufficiently safe for healthcare, mistakes the objection, since the sector's difficulty was never solely that the lending was unregulated but that it was lending, and 15 July altered the adjective rather than the noun.

What do the counterarguments establish?

An opinion piece owes its opponents their strongest case, and three arguments warrant substantive answers.

The access argument holds that private treatment is expensive, that credit widens access, and that refusing instalments constitutes gatekeeping by wealth. It is partly correct, and the reply is architectural rather than dismissive. Monthly-collected supply delivers an identical monthly outlay without the debt, such that the access case for this product specifically resolves into a case for monthly pricing, which this article endorses. What credit adds beyond that is the capacity to owe for treatment already consumed, which constitutes the entanglement rather than the access.

The autonomy argument holds that adults finance holidays and furniture and that paternalism concerning their medicine expenditure is not pharmacy's function. A pharmacy is not neutral retail, however, since the sector holds gatekeeping duties precisely because medicine demand is inelastic, emotionally weighted and clinically consequential, and the autonomy on offer is exercised at a checkout engineered around an urgency which the entire service exists to mediate. Respecting patients entails not constructing the pressure for which they are subsequently held responsible.

The parity argument holds that dentistry, optics, veterinary practice and aesthetics finance treatment routinely, such that pharmacy's reluctance is inconsistent. The honest answer concedes ground. Finance upon a one-off procedure, whether an implant or a lens, constitutes a materially different object, in that the treatment completes at the outset whilst only the debt continues, and this article's position is not principally concerned with those. Ongoing medicine supply differs in kind, since the treatment and the debt run concurrently, default interrupts a course rather than trailing a completed one, and discontinuation carries clinical consequences which a crown does not. Parity reasoning fails precisely where medicines are most distinctively themselves.

What is the scope position on own-book instalments?

One structural detail warrants its own treatment because it will otherwise be misread as an invitation. The new perimeter captures deferred payment credit from third-party lenders, where the lender and the supplier of the goods are different persons, whilst a merchant financing its own sales upon its own book sits, in general, outside it, as such arrangements sat outside previously. A pharmacy could accordingly operate its own instalment arrangement without becoming an FCA-regulated lender.

That position should be read as the difficulty it constitutes rather than the opportunity it resembles. An own-book arrangement carries the entire entanglement, comprising the failed instalment mid-treatment and the pharmacy acting as collector from its own patient, with none of the regime's affordability machinery, none of its forbearance rules, and no lender absorbing the credit risk, the whole resting upon a professional relationship which the GPhC's standards govern even where the FCA's do not. The regulated third-party product is at least an unwise arrangement with guardrails, whilst the unregulated own-book version is the same arrangement with the pharmacy holding every exposure. Falling outside scope constitutes a description rather than an endorsement.

What do the providers' own rules establish?

A quieter obstacle is omitted from the sales materials, namely that the major providers' own acceptable-use and category frameworks have historically restricted medicines and pharmacy, within the same family of policies which this cluster encountered at Stripe and PayPal, and for comparable reasons concerning regulated goods, health risk and brand exposure. Where healthcare instalment credit has grown, it has grown at the margins, across wellness, aesthetics, dentistry and veterinary practice, precisely because medicines sit awkwardly within the lenders' own risk appetite.

That produces the failure mode which this cluster has now documented on three occasions, comprising the category described softly at onboarding, identified at volume, and terminated with settlement consequences. Any pharmacy rejecting this article's position and proceeding regardless inherits the cluster's mechanics unaltered, requiring written category acceptance from an FCA-authorised lender in respect of medicines specifically, or nothing, since the one-line filter does not soften because the product is credit rather than acquiring.

What are the cleaner architectures?

The legitimate need underlying the temptation is genuine, in that private treatment is expensive and affordability determines access. The answer lies in architecture rather than lending.

Price per month of supply and collect as supplied. The subscription model which this cluster has described, operating upon properly authenticated mandates and merchant-initiated billing, charges the patient for each month's medicine as it is dispensed, which delivers the monthly outlay the credit product advertises subject to a structural difference which alters everything, in that the patient never owes for treatment not yet received and ceasing constitutes cancellation rather than default.

Commence with smaller quantities. Starter quantities and shorter first supplies reduce the entry price honestly, and suit titration clinically in any event.

Permit pausing without penalty. A published hardship approach, under which the plan pauses whilst the review is retained and the taper is planned with the prescriber where cessation would be clinically unwise, treats payment failure as a clinical event presenting financially, which within a medicines business is what it is.

Signpost the NHS route. Where an NHS pathway exists, saying so costs a sale and purchases the legitimacy which this site consistently argues constitutes the sector's genuine asset.

None of this constitutes charity. Monthly-collected plans convert the same financially stretched patient whom the credit product courts, at the same monthly price, without manufacturing a debtor, and the pharmacy retains a patient in preference to acquiring a default.

What should be asked when the representative calls?

Since the approach will be made, by newly authorised firms carrying targets, four questions conclude most such discussions honestly.

First, will you confirm in writing acceptance of prescription medicines specifically, rather than wellness or healthcare-adjacent categories, at our product mix, being this cluster's standing filter applied to credit. Second, what occurs, precisely and contractually, when a patient defaults mid-course, covering fees and collections conduct, and what does your firm expect of us clinically whilst it pursues our patient. Third, who bears late-fee and default exposure upon the treatment element, and does any structure exist within which the answer is nobody. Fourth, what patient data flows to you at application and during servicing, upon what lawful basis, and what do your models do with the fact that a person finances medicine, being a question which this site's data protection articles would pose of any partner and which carries unusual weight here.

Propositions surviving all four have earned the meeting. In the author's observation of adjacent markets, most conclude at the first, which constitutes its own answer.

What is the position?

This site's opinion, flagged as such and held following the arguments above, is that pharmacy should not attach consumer credit to medicines, and that the arrival of regulation, which this article welcomes for the wider market, strengthens rather than weakens that position, since respectable instalment credit will now approach healthcare carrying an authorisation certificate and the sector requires its answer prepared.

For operators assessing the question differently, the minimum honest threshold is demanding, comprising an FCA-authorised lender post-Regulation-Day, written medicines-category acceptance, affordability assessment observed rather than circumvented, no late-fee exposure upon the treatment itself, and clinical decisions concerning reviews, tapers and whether to continue kept structurally independent of the patient's standing with the finance partner.

The better answer, however, is the unremarkable one from the preceding section. Price monthly, collect monthly, pause humanely, and permit the lenders to locate a category within which a missed payment costs someone a parcel rather than a treatment plan. Certain checkout facilities are worth less than the conversions they purchase.

Key takeaways

FAQs